SCHEMBL25569475

SCHEMBL25569475

CNC(CF)C(=O)c1ccc2c(c1)SCC2

nearest known ligand 0.32

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
RARA P10276 3/20 0.31
RARB P10826 3/20 0.31
RARG P13631 3/20 0.31
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HTR1B P28222 2/20 0.31
CTNNB1 P35222 1/20 0.30
WNT3A P56704 1/20 0.30
MEN1 O00255 1/20 0.30
GAA P10253 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24197468 0.88 MAPT (0.34) HDAC1HDAC8HDAC6KDM4ENPC1
SCHEMBL25569474 0.88 KDM4E (0.32) HDAC1HDAC8HDAC6KDM4ENPC1
SCHEMBL25569464 0.88 KDM4E (0.32) HDAC1HDAC8HDAC6RARARARB
SCHEMBL25569476 0.87 MAPT (0.32) HDAC1HDAC8HDAC6RARARARB
SCHEMBL25668178 0.86 HDAC1 (0.31) HDAC1HDAC8HDAC6KDM4ENPC1
SCHEMBL25569488 0.85
SCHEMBL25668207 0.84 TAS1R3 (0.35) HDAC1HDAC8HDAC6KDM4ENPC1
SCHEMBL24197476 0.81 HTR1B (0.45) HDAC1HDAC8HDAC6RARARARB
SCHEMBL25569477 0.81 HDAC1 (0.32) HDAC1HDAC8HDAC6KDM4EALDH1A1
SCHEMBL24197470 0.80 MAPT (0.33) HDAC1HDAC8HDAC6KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT SLC6A3, CREBBP, SLC1A2 HDAC1 1235/4885HDAC8 1976/4885HDAC6 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.